Executive Team

Jason Burdette
Senior Vice President - Technical Operations
Jason Burdette has over 25 years experience in the pharmaceutical industry concentrated on formulation and process development, manufacturing, supply chain management and technical operations. He brings extensive experience in new product introduction of multiple products in both the US and international markets. Mr. Burdette joins us from Eagle Pharmaceuticals where he was the VP, Supply Chain. At Eagle he was responsible for supply chain management, procurement, distribution and new product introduction. Mr. Burdette joined Eagle from Shire Pharmaceuticals where he held various positions with increasing responsibility over his 10-year tenure. Including, VP Geographic Expansion Strategy and Planning, Interim Head of Product Strategy, Product Strategy Lead for Vyvanse, Adderall, and Equasym, Global Product Director, Supply Chain for the ADHD business. He was an active member of the supply chain leadership team and the international commercial team among other key executive leadership teams. Prior to Shire Pharmaceuticals, Mr. Burdette worked with aaiPharma, Elan Pharmaceuticals, Sandoz and Mylan Pharmaceuticals.
Michael F. Bigham
Chief Executive Officer and Chairman of the Board
Michael F. Bigham was appointed Chief Executive Officer and Chairman of Paratek Pharmaceuticals, Inc.’s Board of Directors in June 2014 (prior to its merger with Transcept Pharmaceuticals, Inc.). Mr. Bigham has more than 30 years of senior leadership experience in the biopharmaceutical industry. From January 2003 to November 2015, he was a general partner at Abingworth LLP, a leading international investment group dedicated to life sciences and healthcare and part time Executive Partner from November 2015 to August 2018. He currently serves as a member of the board of directors of Adamas Pharmaceuticals and InMediata. He has held several directorships, including at Avila Therapeutics (where he was also the founding Chairman and CEO), Magellan Biosciences, Portola Pharmaceuticals, Supernus Pharmaceuticals, Avedro and Valeritas. Mr. Bigham was formerly Vice Chairman of Corixa Corporation, a publicly traded biotechnology company, and was President and Chief Executive of Coulter Pharmaceuticals, a publicly-traded oncology company, until it merged into Corixa. Previously, he was an early employee at Gilead Sciences where he served in various capacities, including Executive Vice President of Operations and Chief Financial Officer. Before joining Gilead Sciences, Mr. Bigham was a Partner at Hambrecht & Quist where he became Co-Head of Healthcare Investment Banking. Mr. Bigham received his B.S. from the University of Virginia and qualified as a C.P.A. before completing his M.B.A. at Stanford University.
Evan Loh, M.D.
President, Chief Operating Officer and Chief Medical Officer
Evan Loh, M.D. has served as Chief Operating Officer since January 2017 and as President and Chief Medical Officer and a member of the Board of Directors since July 2014. Prior to the merger with Transcept Pharmaceuticals, Dr. Loh was appointed President in June 2014 and served as Chief Medical Officer and Chairman of the Board of Directors from June 2012 to June 2014. Previously, Dr. Loh served as Senior Vice President, Development and Strategic Operations, Worldwide Research and Development, at Pfizer. While at Pfizer, Dr. Loh’s responsibilities included scientific, operational, and strategic drug development oversight for all pre-proof of concept development phase programs and leading portfolio prioritization. Dr. Loh joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President, Multiple Therapeutic Areas where he was responsible for global development strategy and clinical operational deliverables. At Wyeth, he led the successful global registration programs for Torisel and Tygacil. He currently serves on the Board of Directors of Eiger Biopharmaceuticals, Inc. and as Vice Chair of the Antimicrobials Working Group, an industry leading organization of biotech companies focused on antimicrobial development. Dr. Loh served as a director on the Board of Nivalis from 2012 until the completion of its sale to Alpine Immunotherapeutics in 2017. Dr. Loh served as a faculty member at both Harvard Medical School and the University of Pennsylvania School of Medicine. Dr. Loh received his A.B. from Harvard College and his M.D. from Harvard Medical School. He completed his Internal Medicine and Cardiovascular fellowship training at Brigham and Women’s Hospital.
Adam Woodrow
Chief Commercial Officer
Adam Woodrow joined Paratek in October 2014 to lead the commercialization of Paratek’s product portfolio. Adam previously worked for Pfizer for five years in various strategic and operational commercial roles. While at Pfizer, Adam led the commercial development group in Pfizer's Specialty Care Business Unit, launching Xeljanz® for Rheumatoid Arthritis and Vyndaqel® for the treatment of Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). In addition, Adam led the global strategic marketing teams for a variety of products in fields ranging from rare disease to acute hospital based infections; major products included Enbrel®, Zyvox®, ReFacto® and Benefix®. Adam joined Pfizer from Wyeth Pharmaceuticals, where he was Vice President and Global Business Manager for Enbrel leading all commercial aspects of Wyeth's inflammation portfolio, co-promotion, licensing, and product development. In his 10 years at Wyeth, Adam held senior marketing and sales positions in the US and in his native UK. He was responsible for the successful launches of medicines in the fields of anti-infectives (Tygacil®), hemophilia (ReFacto), primary immune deficiency and women's health. Before joining Wyeth, Adam held sales and marketing positions with Bayer Pharmaceuticals. During his career in the pharmaceutical industry, Adam has worked with several non-profit societies and organizations. Adam has a Bachelor of Science degree in Industrial Chemistry from the University of Wales College of Cardiff.
William Haskel
General Counsel and Corporate Secretary
William Haskel joined Paratek in June 2015 as Senior Vice President, General Counsel and Corporate Secretary. From 2011 until March 2015, Bill served as the Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary at Cambrex Corporation, where he reported to the CEO, and was a member of core management committees. Bill provided counsel to the Board of Directors, CEO, and senior management, and was responsible for the global law function as well as overseeing Global Regulatory and Quality Affairs, and Environment, Health and Safety and was a principal adviser for Board and Governance, M&A, Securities and Corporate matters. Previously, Bill enjoyed an 18 year career of progressive responsibilities at Wyeth, which was acquired by Pfizer in 2009 in a transaction valued at $68 billion. Bill served as Vice President and Associate General Counsel-Corporate where he was a key advisor to executive management and managed a group of 33 employees/19 lawyers across corporate and pharmaceutical division headquarters, and led legal teams on a series of complex multi-billion dollar global transactions that drove the Company's transition from a diversified holding company to a focused health care company. Bill also served as Vice President, Global Administration where he led a newly formed global department charged with designing and executing global strategies to capture cost savings and business efficiencies in light of the new health care environment. During this time, Bill also served as Advisor for the Pfizer Transaction and was a leader of the successful integration of Wyeth into Pfizer. Earlier at Wyeth, Bill was selected to be the Assistant Vice President, Planning; Assistant to the Chairman, President and CEO; and Secretary of Wyeth Management Committee. Earlier in his career, Bill was a corporate associate at the law firms Hale & Dorr (now WilmerHale) in Boston, and Olwine, Connelly, Chase, O'Donnell & Weyher in New York City. He received his J.D. from George Washington University Law School; his B.A. from Franklin and Marshall College; and has Bar Admissions in New York State; Commonwealth of Massachusetts; New Jersey (Limited In-House License), and the United States District Court (District of Massachusetts).
Randy Brenner
Senior Vice President - Regulatory, Quality and Technical Operations
Randy Brenner has over 20 years of pharmaceutical and regulatory experience in leading the development and registration of products across many different regions and therapeutic areas, including anti-infectives. Mr. Brenner comes to us from Shire where he was the Global Head of Regulatory Affairs at Shire Pharmaceuticals. At Shire he was responsible for all aspects of regulatory for a broad range of programs in multiple therapeutic areas and pharmaceutical technologies. He was a member of key executive leadership teams and helped contribute to the growth of Shire through critical programs and product approvals over the last three and a half years. Mr. Brenner joined Shire from Pfizer where he was Head of Regulatory Affairs for the Emerging Markets and Established Products Business Units. In this role he played an active part on the regional leadership teams and was responsible for the regulatory activities and staff leading the development, registration, launch, and life cycle of all of Pfizer's innovative products outside the United States and European Union as well as the Established Products business in all regions. Under his leadership many significant regulatory accomplishments were achieved ranging from the global expansion of Pfizer's programs to establishing important relationships and innovated approaches to development with key regulatory agencies in Asia, Latin America, and other key growth regions. Prior to Pfizer Randy spent 14 years at Wyeth Pharmaceuticals, where he held multiple senior regulatory positions. His leadership and regulatory capabilities contributed to the successful development, registration and launch of many new products (including Tygacil) and important life cycle expansions in many different therapeutic areas including those in the field of anti-infectives.
Evan Tzanis
Chief Development Officer
Evan Tzanis joined Paratek in September 2014 as Vice President of Clinical Development to oversee clinical development strategic and operational deliverables including the design/oversight of clinical trials, biometrics and regulatory affairs. Mr. Tzanis brings over 20 years of global drug development experience in all aspects of clinical, operational, and regulatory processes. Prior to joining Paratek, Mr. Tzanis served as Head of Clinical Operations and Biometrics at Endo Pharmaceuticals where he also had leadership responsibility in clinical and project management. During his tenure with Endo, Mr. Tzanis was responsible for a number of late stage development programs, including BEMA® Buprenorphine, which successfully completed Phase 3. Prior to joining Endo, Mr. Tzanis was the Global Clinical Program Leader at Wyeth and Pfizer for a number of successful new products on the market today to treat a range of CNS disorders including panic disorder, major depressive disorder, sleep and other medical conditions, including opioid induced constipation and rheumatoid arthritis.